Sanofi's GLP-1 combo LixiLan bests both its ingredients in late-stage studies - FiercePharma

FiercePharma

Sanofi's GLP-1 combo LixiLan bests both its ingredients in late-stage studies FiercePharma NEW ORLEANS—As Sanofi's top-selling Lantus careens toward its first U.S. biosimilar competition in December, the French drugmaker has not only been developing a follow-up diabetes product — the longer-acting Toujeo, FDA-approved last year — but a ... Sanofi says LixiLan diabetes drug trials meet targetsReuters Positive results from pivotal Phase III clinical trials with iGlarLixi presented at the American Diabetes ...GlobeNewswire (press release) Sanofi Announces Positive Phase 3 Results for Investigational Titratable Fixed-Ratio Combination of Insulin Glargine ...Stock Transcript all 4 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNEoZRDV4i-nCVVUrVUujrCCMuGOfg&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779132222953&ei=WtpdV8imFYrP3QG_lo2QBQ&url=http://www.fiercepharma.com/pharma/sanofi-s-glp-1-combo-lixilan-bests-both-its-ingredients-late-stage-studies
via IFTTT